The 2nd International Conference on the Latest Researches, Experience Sharing on SINOVAC's COVID-19 Vaccine Was Held
Beijing，November 18, 2021, the 2nd International Conference on the Latest Researches and Experience Sharing on SINOVAC's COVID-19 Vaccine hosted by SINOVAC Biotech Ltd (SIONVAC). was held successfully. The conference was held online, at which domestic and overseas experts gathered together and communicated about "clinical research and application of COVID-19 inactivated vaccine", including Budi Gunadi Sadikin, Minister of Health of the Republic of Indonesia; Carlito Galvez Jr. Presidential Peace Advisor&Chief National Coordinator against COVID-19; Datuk Zulkanain, Group Managing Director of Pharmaniaga Berhad; Alexis Kalergis professor of Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, and Director of Immunotherapy Institute; Dr. Xiangxi WANG, Researcher of Institute of Biophysics, Chinese Academy of Sciences; Dr. Xiaoqiang LIU, Director of the Vaccine Clinical Research Center, Yunnan Center for Disease Control and Prevention; CDC; Dr. Zijie ZHANG, Researcher of State Key Laboratory of Conservation and Utilization of Bio-resources, Yunnan University; and Dr. Minjie LI Vaccine Clinical Institute, Hebei CDC. The conference was hosted by prof. Yiming SHAO, Member of Vaccine R&D Expert Group of the Joint Prevention and Control Mechanism of the State Council and Investigator of China CDC. Ms. Helen YANG, Chief Business Officer of SINOVAC and Mr. Weining MENG, Vice President of SINOVAC Hong Kong, attended the conference and delivered speeches. Nearly 1,000 officials in disease prevention and control, experts and scholars from about 40 countries attended the conference online.
H.E. Carlito Galvez Jr., Philippine National Task Force against COVID-19 chief implementer and vaccine, showed affirmation of SINOVAC. He said that, in the early stage of the epidemic, there was an inadequate vaccine supply, SINOVAC's stable, sustained, and massive vaccine supply helped the Philippines to successfully launch the national vaccination program in March this year, and helped the Philippines achieve the goal of vaccinating 1.5million people per day. SINOVAC is a very reliable partner."On behalf of the Philippine government and people, I would like to express my gratitude to SINOVAC scientific and all those who have helped the Philippines fight the epidemic".
H.E. Budi Gunadi Sadikin, Minister of Health of the Republic of Indonesia, shared the latest strategy of Indonesia' National Covid-19 immunization program and the best practice. He emphasized that, the early and rapid supply of SINOVAC COVID-19 vaccine CoronaVac® allowed Indonesia to quickly implement national COVID-19 vaccination. In the later period, although Indonesia approved more kinds of vaccines, the increase of adverse reactions caused the decrease in people's acceptance for vaccination. At present, the government of Indonesia is strengthening publicity that all vaccines available are effective and safe, in the hope of increasing the vaccination coverage.
Dr. Xiangxi WANG shared the study results of serology and compound structure of COVID-19 neutralizing antibody and antigen after a third dose of SINOVAC inactivated vaccine. In his view, a third dose of inactivated vaccine could recall humoral immunity rapidly and durably. Such immunity is more effective and the breadth of the neutralizing antibody is significantly strengthened. Besides, it showed good cross-neutralization effect on alpha, beta, gamma and Delta variants. Similar to mRNA vaccines, more than 80% of subjects had a decrease in the neutralizing antibody titer 6 months after received the second dose of COVID-19 inactivated vaccine. But, the neutralizing antibody titer increased by about 20 times 2 weeks after the inoculation of the third dose of COVID-19 inactivated vaccine. It's worth noting that, 180 days after the third dose of the inactivated vaccine, the neutralizing antibody titer still maintained at the same level as the peak antibody titer after the second dose.
Dr. Xiaoqiang LIU, Yunnan CDC, introduced the interim results of multi-center safety studies of CoronaVac® with the sample size of 121,000 aged 18 years or above from 30 counties, 11 provinces across China. The results showed that, the adverse reaction rate caused by CoronaVac® was about 2.52%, manly including grade 1 and grade 2 mild adverse reactions such as local pain and fatigue. CoronaVac® showed good safety in the population aged 18 years or above (including those with underlying diseases).
Dr. Minjie LI from Hebei CDC later introduced the study results on Phase I/II clinical trial and immune persistence of CoronaVac® in 3-17 children. The results showed good safety and immunogenicity of the vaccine in healthy pediatric aged 3-17 years. It's worth noting that, the positive conversion rate of the neutralizing antibody and the antibody titer level in minors basically remained stable at a certain level within 3 months after the second dose of the vaccine. But at the 6th month, the antibody level dropped significantly, indicating that both children and adolescents should also receive a third dose of the vaccine.
Dr. Zijie Zhang from Yunnan University shared immunogenicity and safety research results of SINOVAC CoronaVac® inactivated vaccine in patients with 6 underlying medical conditions. This study focus on immunogenicity and safety of CoronaVac® in patients with 6 types of common chronic diseases including coronary artery diseases, chronic respiratory disease, diabetes, obesity, cancer (after treatment), and hypertension. Overall, the adverse reaction rate, the positive conversion rate of the neutralizing antibody and the titer level in the people with the 6 types of underlying medical conditions after two doses of CoronaVac® showed no statistical difference with those in healthy people, suggesting that CoronaVac® is also safe and effective for the patients with the 6 types of chronic diseases.
Dr. Alexis Kalergis from Pontificia Universidad Católica de Chile reviewed the immunogenicity and safety data of Phase III clinical trials of SINOVAC CoronaVac® inactivated vaccine in Chile with different procedures and different populations. He said that CoronaVac® is a well-tolerated vaccine in the entire population with a low local and systematic adverse reaction rate. CoronaVac® induces antibody production in more than 90% of subjects and the expansion of SARS-CoV-2-specific T cells that protect against COVID-19. Compared with other types of COVID-19 vaccines in Chile, CoronaVac® has shown one of the lowest incidences of side effects.
At the end of the conference, Ms. Helen (Guang) YANG expressed her thanks to all the experts and scholars attending the conference and scientists whom contributed in the research. She empohasized that, as the global COVID-19 pandemic continues, the safety of the vaccine is the key factor to achieve sufficient vaccination coverage. Just like the research results shared by experts at the conference, CoronaVac® is safe and effective for pediatric population, adolescents, healthy adults, the elderly, and those with underlying medical conditions. We are working with partners in more than a dozen of countries on joint vaccine research and local production, and continuing our commitment to make vaccines more accessible and affordable around the world. So far, SINOVAC has supplied more than 2.2 billion doses of CoronaVac® globally, and more than 1.8 billion doses have been applied, making it the largest supplied and administered COVID-19 vaccine globally and in China. We will continue our innovative research on vaccines. SINOVAC is willing to work with more partners around the world to provide safer and more effective vaccines for the world.
On March 22, 2021, the 1st International Conference on the Latest Researches and experience sharing on SINOVAC's COVID-19 Vaccine and National Immunization Program hosted by SINOVAC was held at Diaoyutai State Guest House, Beijing. Ambassadors and counselors to China from 22 countries as well as a number of experts from China CDC attended the conference. Besides, more than 2,000 persons including experts and scholars from 42 countries and relevant international organizations, as well as experts from domestic disease control systems at all levels, participated online.
( https://mp.weixin.qq.com/s/4GP6SZHUGMz1SkJksMHTzg )
SINOVAC Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases. SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus71 (EV71), hepatitis A and B, seasonal influenza, 23-Valent pneumococcal polysaccharide ("PPV"), H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), varicella and mumps. SINOVAC's COVID-19 vaccine,
CoronaVac®, has been granted emergency use approval or conditional marketing authorization by over 40countries or regions worldwide. Healive®, the hepatitis A vaccine manufactured by the Company, has passed the assessment under WHO prequalification procedures in 2017. The EV71 vaccine, an innovative vaccine developed by SINOVAC against hand foot and mouth disease caused by EV71, was commercialized in China in 2016. In 2009, SINOVAC was the first company worldwide to receive approval for its H1N1 influenza vaccine, which it has supplied to the Chinese Government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine to the government stockpiling program. The Company is developing several new products including a Sabin-strain inactivated polio vaccine and combined vaccines. SINOVAC primarily sells its vaccines in China, while also exploring growth opportunities in international markets. The Company is seeking market authorization of its products in over 30 countries outside of China. For more information, please see the Company's website at www.sinovac.com.
Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the research, development, manufacturing, and commercialization of vaccines that protect against human infectious diseases.
SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A and B, seasonal influenza, pneumococcal disease, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), varicella, mumps, and poliomyelitis.
SINOVAC's COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The Healive®, a hepatitis A vaccine manufactured by the Company, passed the assessment under WHO prequalification procedures in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine, that was commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) was prequalified by WHO.
SINOVAC was the first company that granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied to the Chinese Government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program.
SINOVAC has been continually dedicating itself to new vaccine research and development, with more combination vaccine products in the pipeline, and constantly exploring opportunities in the international market. SINOVAC looks forward to conducting more extensive and in-depth trade and cooperation with more countries, enterprises, and professional institutions.
For more information, please see the Company’s website at www.sinovac.com.
Sinovac Biotech Ltd.